NEW YORK, Oct. 22, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) SUPN. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.
The investigation concerns whether Supernus and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On October 10, 2022, Supernus issued a press release announc[ing] that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the SPN-830 New Drug Application (NDA).” Supernus stated that “[t]The CRL requires additional information and analysis related to the infusion device and drug product in several areas of the NDA including, but not limited to, labeling, product quality and manufacturing, device performance, and risk analysis. Additionally, the FDA mentions that the NDA approval requires inspections that could not be completed in a timely manner due to COVID-19 travel restrictions.”
As a result of this news, Supernus’ stock price fell $1.55 per share, or 4.66%, to close at $31.74 per share on October 10, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.
[ad_2]
Source story
